Facebook Linkedin RSS Twitter Youtube
Home 2024

MorphoSys

Novartis to Acquire MorphoSys for $2.9B, Bolstering Oncology Pipeline
Cancer

Novartis to Acquire MorphoSys for $2.9B, Bolstering Oncology Pipeline

StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M
Cancer

StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M

Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal
Cancer

Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal

GSK Advances Arthritis Candidate into Phase III, Triggering €22M Milestone Payment to MorphoSys
Industry News

GSK Advances Arthritis Candidate into Phase III, Triggering €22M Milestone Payment to MorphoSys

Top 10 Biopharma IPOs of January–June 2018
A-Lists

Top 10 Biopharma IPOs of January–June 2018

MorphoSys, Emergent to Develop Prostate Cancer Candidate
Cancer

MorphoSys, Emergent to Develop Prostate Cancer Candidate

MorphoSys and BI Sign Process Development and Manufacturing Deal for CLL mAb
Bioprocessing

MorphoSys and BI Sign Process Development and Manufacturing Deal for CLL mAb

MorphoSys and Proteros Get €850K to Develop Technology to Analyze Ab-Ag Complexes
Drug Discovery

MorphoSys and Proteros Get €850K to Develop Technology to Analyze Ab-Ag Complexes

German Government Grants MorphoSys $1.26M to Progress Multiple Myeloma Antibody into Clinic
Cancer

German Government Grants MorphoSys $1.26M to Progress Multiple Myeloma Antibody into Clinic

MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up Front
Cancer

MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up Front

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.